Edgewise Therapeutics Inc. Common Stock vs Nucor Corporation — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.03 (market cap $3.94B), while Nucor Corporation trades at $257.14 (market cap $57.58B). The key difference: Nucor Corporation is far larger — about 14.6× Edgewise Therapeutics Inc. Common Stock's market cap, and Nucor Corporation pays a 0.88% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Nucor Corporation for 78 Days on average.
| EWTX | NUE | |
|---|---|---|
Market Cap | $3.94B | $57.58B |
Volume | 810,104 | 874,073 |
Sector | Health | Basic Materials |
52-Week High | $48.35 | $274.74 |
52-Week Low | $14.89 | $131.78 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $3.48B | $61.99B |
Dividend Yield | — | 0.88% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nucor (NUE) trades at $257.11, up 2.1% today, showing strong momentum with a 50% gain over six months. The stock is in a bullish technical trend, supported by recent earnings beats in Q1 and Q2 2026. Fundamentals reflect solid profitability with a 7.99% net margin and 13.52% ROE, though revenue has moderated from 2022 peaks. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% and recently declared its 214th consecutive dividend.
Outlook remains positive with analyst consensus at 'Buy' and a $266.88 price target, though near-term risks include competitive pressures from new steel capacity and volatility in steel prices. Earnings growth and operational efficiency are key catalysts, but investors should monitor Q3 2026 results against expectations of $5.80 EPS.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →